SL
Silence Therapeutics plc
SLN · NASDAQ
$12.20 -2.63% (-$0.33)
1M -8.06%
Market Cap $599.9M
P/E Ratio -
Div. Yield -
ROE 106.90%
Piotroski F-Score Weak
1/9Valuation
0 /100
Expensive P/B 15.59x
P/S 976.52x
EV/FFO N/A
Growth
22 /100
Declining Book val. growth 41.33%
Rev. growth 68.36%
FCF growth N/A
Profitability
20 /100
Weak Op. margin 11,003.00%
Gross margin 51.00%
FCF margin 6,893.22%
Quality
0 /100
Poor ROA 56.32%
ROIC 176.21%
Asset turnover 0.01x
Debt
33 /100
High Current ratio 7.42x
Debt/Equity -0.00x
Debt/Assets N/A
Stability
41 /100
Moderate EPS volatility 11.98%
Beta 1.41x
Profitable years 0
Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe
Întreabă StockBot despre SLN
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Iain Gladstone Ross
Employees
88
Headquarters
London
Evenimente viitoare
05 NOV.
Earnings
Upcoming earnings report